Scottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through clinical development.
https://european-biotechnology.com/wp-content/uploads/2026/08/robina-weermeijer-szKjHyPq28-unsplash-scaled.jpg14402560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-08-06 10:17:252026-08-06 11:33:03Mironid lands $46M Series B to take kidney drug into clinic
French biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer.
AstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement.
https://european-biotechnology.com/wp-content/uploads/2026/08/getty-images-jPswZjwauds-unsplash-scaled.jpg17072560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-08-04 11:21:242026-08-04 11:21:24AstraZeneca taps Pathos for breast cancer degrader
Ipsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery.
https://european-biotechnology.com/wp-content/uploads/2026/08/fellipe-ditadi-ulqJPAhXMqM-unsplash.jpg63369504Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-08-03 17:49:192026-08-03 17:49:19Ipsen quietly returns cancer drug IPN01194 to AGV Discovery
Guido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue more than fivefold.
https://european-biotechnology.com/wp-content/uploads/2026/08/Guido_Oelkers_0.png13822074Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-08-03 11:44:432026-08-13 11:46:12Sobi’s dealmaker CEO exits for BioNTech
AstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.
Novo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales.
UK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million.
https://european-biotechnology.com/wp-content/uploads/2026/07/kateryna-hliznitsova-3dg8Jn-yw58-unsplash.jpg55048256Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-31 15:53:262026-07-31 15:53:26Pharmanovia licenses China-approved PARP drug for up to €423.5M
London-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to predict how human cells respond to experimental treatments.
Sanofi has discontinued development of itepekimab and balinatunfib after disappointing clinical results, ending ongoing programmes across respiratory and inflammatory diseases.
https://european-biotechnology.com/wp-content/uploads/2026/07/abby-savage-9Urds43o8c-unsplash-scaled.jpg17022560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-30 11:09:122026-07-30 11:09:12Sanofi axes two more inflammatory-disease drugs
Mironid lands $46M Series B to take kidney drug into clinic
Latest NewsScottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through clinical development.
Evexta pairs ex-Merck drug with Roche’s giredestrant
Latest NewsFrench biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer.
AstraZeneca taps Pathos for breast cancer degrader
Latest NewsAstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement.
Ipsen quietly returns cancer drug IPN01194 to AGV Discovery
Latest NewsIpsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery.
Sobi’s dealmaker CEO exits for BioNTech
Latest NewsGuido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue more than fivefold.
AstraZeneca explores $400B combination with BMS
Latest NewsAstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.
ZEUS failure clouds future of Novo’s cardiovascular plans
Latest NewsNovo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales.
Pharmanovia licenses China-approved PARP drug for up to €423.5M
Latest NewsUK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million.
Relation deepens GSK alliance with $110M deal
Latest NewsLondon-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to predict how human cells respond to experimental treatments.
Sanofi axes two more inflammatory-disease drugs
Latest NewsSanofi has discontinued development of itepekimab and balinatunfib after disappointing clinical results, ending ongoing programmes across respiratory and inflammatory diseases.